{ "labelLang" : "hun", "responseDate" : "2024-03-29 16:27", "content" : { "otype" : "JournalArticle", "mtid" : 25176436, "status" : "ADMIN_APPROVED", "published" : true, "unhandledTickets" : 0, "oldTimestamp" : "2017-10-27T19:24:51.000+0000", "deleted" : false, "oldId" : 15176436, "lastRefresh" : "2023-07-15T16:21:20.984+0000", "lastModified" : "2020-06-19T09:49:47.056+0000", "created" : "2015-11-23T15:56:55.000+0000", "creator" : { "otype" : "Author", "mtid" : 10003196, "link" : "/api/author/10003196", "label" : "Kovács Péter (Klinikai farmakológia)", "familyName" : "Kovács", "givenName" : "Péter", "published" : true, "oldId" : 10003196, "snippet" : true }, "lastDuplumOK" : "2020-06-19T09:49:33.952+0000", "lastDuplumSearch" : "2020-06-19T09:49:33.952+0000", "adminApproved" : "2020-06-19T09:49:47.069+0000", "adminApprover" : { "otype" : "Admin", "mtid" : 10067746, "link" : "/api/admin/10067746", "label" : "Király Magdolna (DE admin 4)", "familyName" : "Király", "givenName" : "Magdolna", "published" : true, "snippet" : true }, "core" : false, "citation" : true, "publicationPending" : false, "type" : { "otype" : "PublicationType", "mtid" : 24, "link" : "/api/publicationtype/24", "label" : "Folyóiratcikk", "code" : 24, "otypeName" : "JournalArticle", "listPosition" : 1, "published" : true, "oldId" : 24, "snippet" : true }, "subType" : { "otype" : "SubType", "mtid" : 1134514, "link" : "/api/subtype/1134514", "label" : "Összefoglaló cikk (Folyóiratcikk)", "name" : "Összefoglaló cikk", "nameEng" : "Survey paper", "docType" : { "otype" : "PublicationType", "mtid" : 24, "link" : "/api/publicationtype/24", "label" : "Folyóiratcikk", "code" : 24, "otypeName" : "JournalArticle", "listPosition" : 1, "published" : true, "oldId" : 24, "snippet" : true }, "listPosition" : 102, "published" : true, "oldId" : 1134514, "snippet" : true }, "category" : { "otype" : "Category", "mtid" : 1, "link" : "/api/category/1", "label" : "Tudományos", "published" : true, "oldId" : 1, "snippet" : true }, "languages" : [ { "otype" : "Language", "mtid" : 10012, "link" : "/api/language/10012", "label" : "Spanyol", "name" : "Spanyol", "nameEng" : "Spanish", "published" : true, "oldId" : 13, "snippet" : true } ], "firstAuthor" : "Fridman, O", "authorships" : [ { "otype" : "PersonAuthorship", "mtid" : 43000473, "link" : "/api/authorship/43000473", "label" : "Fridman, O", "listPosition" : 1, "share" : 0.0, "first" : true, "last" : false, "familyName" : "Fridman", "givenName" : "O", "authorTyped" : true, "editorTyped" : false, "otherTyped" : false, "type" : { "otype" : "AuthorshipType", "mtid" : 1, "link" : "/api/authorshiptype/1", "label" : "Szerző", "code" : 0, "published" : true, "oldId" : 0, "snippet" : true }, "published" : false, "oldId" : 74623376, "snippet" : true }, { "otype" : "PersonAuthorship", "mtid" : 43000474, "link" : "/api/authorship/43000474", "label" : "Fuchs, AG", "listPosition" : 2, "share" : 0.0, "first" : false, "last" : false, "familyName" : "Fuchs", "givenName" : "AG", "authorTyped" : true, "editorTyped" : false, "otherTyped" : false, "type" : { "otype" : "AuthorshipType", "mtid" : 1, "link" : "/api/authorshiptype/1", "label" : "Szerző", "code" : 0, "published" : true, "oldId" : 0, "snippet" : true }, "published" : false, "oldId" : 74623375, "snippet" : true }, { "otype" : "PersonAuthorship", "mtid" : 43000475, "link" : "/api/authorship/43000475", "label" : "Porcile, R", "listPosition" : 3, "share" : 0.0, "first" : false, "last" : false, "familyName" : "Porcile", "givenName" : "R", "authorTyped" : true, "editorTyped" : false, "otherTyped" : false, "type" : { "otype" : "AuthorshipType", "mtid" : 1, "link" : "/api/authorshiptype/1", "label" : "Szerző", "code" : 0, "published" : true, "oldId" : 0, "snippet" : true }, "published" : false, "oldId" : 74623374, "snippet" : true }, { "otype" : "PersonAuthorship", "mtid" : 43000476, "link" : "/api/authorship/43000476", "label" : "Morales, AV", "listPosition" : 4, "share" : 0.0, "first" : false, "last" : false, "familyName" : "Morales", "givenName" : "AV", "authorTyped" : true, "editorTyped" : false, "otherTyped" : false, "type" : { "otype" : "AuthorshipType", "mtid" : 1, "link" : "/api/authorshiptype/1", "label" : "Szerző", "code" : 0, "published" : true, "oldId" : 0, "snippet" : true }, "published" : false, "oldId" : 74623373, "snippet" : true }, { "otype" : "PersonAuthorship", "mtid" : 43000477, "link" : "/api/authorship/43000477", "label" : "Gariglio, LO", "listPosition" : 5, "share" : 0.0, "first" : false, "last" : true, "familyName" : "Gariglio", "givenName" : "LO", "authorTyped" : true, "editorTyped" : false, "otherTyped" : false, "type" : { "otype" : "AuthorshipType", "mtid" : 1, "link" : "/api/authorshiptype/1", "label" : "Szerző", "code" : 0, "published" : true, "oldId" : 0, "snippet" : true }, "published" : false, "oldId" : 74623372, "snippet" : true } ], "title" : "Paraoxonase: Its multiple functions and pharmacological regulation", "altTitles" : "Paraoxonasa: Sus múltiples funciones y regulación farmacológica", "identifiers" : [ { "otype" : "PublicationIdentifier", "mtid" : 9973149, "link" : "/api/publicationidentifier/9973149", "label" : "Scopus: 84859533461", "source" : { "otype" : "PlainSource", "mtid" : 3, "link" : "/api/publicationsource/3", "label" : "Scopus", "type" : { "otype" : "PublicationSourceType", "mtid" : 10003, "link" : "/api/publicationsourcetype/10003", "label" : "Indexelő adatbázis", "mayHaveOa" : false, "published" : true, "snippet" : true }, "name" : "Scopus", "linkPattern" : "http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-@@@", "publiclyVisible" : true, "published" : true, "oldId" : 3, "snippet" : true }, "validState" : "IDENTICAL", "idValue" : "84859533461", "realUrl" : "http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-84859533461", "published" : false, "oldId" : 10623912, "snippet" : true } ], "journal" : { "otype" : "Journal", "mtid" : 10005918, "link" : "/api/journal/10005918", "label" : "ARCHIVOS DE CARDIOLOGIA DE MEXICO 1405-9940 1665-1731", "pIssn" : "1405-9940", "eIssn" : "1665-1731", "reviewType" : "REVIEWED", "noIF" : false, "sciIndexed" : true, "scopusIndexed" : true, "lang" : "FOREIGN", "hungarian" : false, "published" : true, "oldId" : 10005918, "snippet" : true }, "volume" : "81", "issue" : "3", "firstPage" : "251", "lastPage" : "260", "firstPageOrInternalIdForSort" : "251", "pageLength" : 10, "publishedYear" : 2011, "digital" : null, "printed" : null, "sourceYear" : 2015, "packet" : "(Kovács Péter (Klinikai farmakológia); 2015.11.23. 16:56:26)", "foreignEdition" : true, "foreignLanguage" : true, "fullPublication" : true, "conferencePublication" : false, "nationalOrigin" : false, "missingAuthor" : false, "oaType" : "GOLD", "oaCheckDate" : "2023-07-15", "oaFree" : false, "oaLink" : "http://www.medigraphic.com/archivoscardiologia/index.htm", "citationCount" : 0, "citationCountUnpublished" : 0, "citationCountWoOther" : 0, "independentCitCountWoOther" : 0, "doiCitationCount" : 0, "wosCitationCount" : 0, "scopusCitationCount" : 0, "independentCitationCount" : 0, "unhandledCitationCount" : 0, "citingPubCount" : 0, "independentCitingPubCount" : 0, "unhandledCitingPubCount" : 0, "citedPubCount" : 6, "citedCount" : 6, "ratings" : [ { "otype" : "SjrRating", "mtid" : 5711582, "link" : "/api/sjrrating/5711582", "label" : "sjr:Q4 (2011) Scopus - Cardiology and Cardiovascular Medicine ARCHIVOS DE CARDIOLOGIA DE MEXICO 1405-9940", "listPos" : 248, "rankValue" : 1.0, "type" : "journal", "ratingType" : { "otype" : "RatingType", "mtid" : 10002, "link" : "/api/ratingtype/10002", "label" : "sjr", "code" : "sjr", "published" : true, "snippet" : true }, "subject" : { "otype" : "ClassificationExternal", "mtid" : 2705, "link" : "/api/classificationexternal/2705", "label" : "Scopus - Cardiology and Cardiovascular Medicine", "published" : true, "oldId" : 2705, "snippet" : true }, "ranking" : "Q4", "calculation" : "DIRECT", "published" : true, "oldId" : 5711582, "snippet" : true } ], "ratingsForSort" : "Q4", "referenceList" : "Fridman, O., D'Eramo, J.L., Finkelstein, A.E., Homocisteina plasmática: Factor de riesgo independiente de afecciones vasculares oclusivas (1997) Revista Argentina De Cardiología, 65, pp. 571-581; \n\nFridman, O., Hiperhomocisteinemia: Aterotrombosis y neurotoxicidad (1999) Acta Physiol Pharmacol Ther Latinoam, 49, pp. 21-30; \n\nLawrence de Konig, A.B., Werstuck, G.H., Zhou, J., Hyperhomocysteinemia and its role in the development of atherosclerosis (2003) Clin Biochem, 36, pp. 431-441; \n\nJakubowski, H., Calcium-dependent human serum homocysteine thiolactone hydrolase. A protective mechanism against protein N-homocysteinylation (2000) J Biol Chem, 275, pp. 3957-3962; \n\nJakubowski, H., The pathophysiological hypothesis of homocysteine thiolactone-mediated vascular disease (2008) J Physiol Pharmacol, 59, pp. 155-167; \n\nBełtowski, J., Protein homocysteination: A new mechanism of atherogenesis? (2005) Post Hig Med Dośw, 59, pp. 392-404; \n\nPerla-Kaján, J., Jakubowski, H., Paraoxonase 1 protects against protein N-homocysteinylation in humans (2010) FASEB J, 24, pp. 931-936; \n\nMercie, P., Garmier, O., Lascoste, L., Homocysteine thiolactone induces caspase-independent vascular endothelial cell death with apoptotic features (2000) Apoptosis, 5, pp. 403-411; \n\nHuang, R.F., Huang, S.M., Lin, B.S., Homocysteine thiolactone induces apoptotic DNA damage mediated by increased intracellular hydrogen peroxide and caspase 3 activation in HL60 cells (2001) Life Sci, 68, pp. 2799-2811; \n\nNajib, S., Sanchez-Margalet, V., Homocysteine thiolactone inhibits insulin signaling and glutathione has a protective effect (2001) J Mol Endocrinol, 27, pp. 85-91; \n\nMazur, A., An enzyme in animal tissues capable of hydrolyzing the phosphorus-fluorine bond of alkyl fluorophosphates (1946) J Biol Chem, 164, pp. 271-289; \n\nMackness, M.I., Mackness, B., Durrington, P.N., Paraoxonase: Biochemistry, genetics and relationship to plasma lipoproteins (1996) Curr Opin Lipidol, 7, pp. 69-76; \n\nLotti, M., The pathogenesis of organophosphate polyneuropathy (1991) Crit Rev Toxicol, 21, pp. 465-487; \n\nCosta, L.G., Cole, T.B., Jarvik, G.P., Functional genomic of the paraoxonase (PON1) polymorphisms: Effects on pesticide sensitivity, cardiovascular disease, and drug metabolism (2003) Annu Rev Med, 54, pp. 371-392; \n\nla Du, B.N., Human serum paraoxonase/arylesterase (1992) Pharmacogenetics of Drug Metabolism, pp. 51-91. , ed. W. Kalow. Pergamon Press, New York; \n\nMackness, M.I., Arrol, S., Durrington, P.N., Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein (1991) FEBS Lett, 286, pp. 152-154; \n\nBillecke, S., Draganov, D., Counsell, R., Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters (2000) Drug Metab Dispos, 28, pp. 1335-1342; \n\nKaźmierski, R., łaciński, M., Progress in the research on the genetic factors influencing the development of carotid and cerebral atherosclerosis (2002) Aktualności Neurologiczne, 2, pp. 8-16; \n\nDomagala, T.B., Lacinski, M., Trzeciak, W.H., The correlation of homocysteine-thiolactonase activity of the paraoxonase (PON1) protein with coronary heart disease status (2006) Cell Mol Biol, 52, pp. 4-10; \n\nPrimo-Parmo, S.L., Sorenson, R.C., Teiber, J., The human serum paraoxonase / arylesterase gene (PON1) is one member of a multigene family (1996) Genomics, 33, pp. 498-507; \n\nKobayashi, M., Shinohara, M., Sakoh, C., Lactone-ring-cleaving enzyme: Genetic analysis, novel RNA editing, and evolutionary implications (1998) Proc Natl Acad Sci USA, 95, pp. 12787-12792; \n\nNg, C.J., Wadleigh, D.J., Gangopadhyay, A., Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell-mediated oxidative modification of low density lipoprotein (2001) J Biol Chem, 276, pp. 44444-44449; \n\nBlatter, M.C., James, R.W., Messmer, S., Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-45. Identity of K-45 with paraoxonase (1993) Eur J Biochem, 211, pp. 871-879; \n\nDeakin, S., Leviev, I., Gomaraschi, M., Enzymatically active paraoxonase-1 is located at the external membrane of producing cells and released by a high affinity, saturable, desorption mechanism (2002) J Biol Chem, 277, pp. 4301-4308; \n\nHarel, M., Aharoni, A., Gaidukov, L., Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes (2004) Nat Struct Mol Biol, 11, pp. 412-419; \n\nHumbert, R., Adler, D.A., Disteche, C.M., The molecular basis of the human serum paraoxonase activity polymorphism (1993) Nat Genet, 3, pp. 73-76; \n\nDavies, H.G., Richter, R.J., Keifer, M., The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin (1996) Nat Genet, 14, pp. 334-336; \n\nAviram, M., Hardak, E., Vaya, J., Human serum paraoxonase (PON) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase-like activities (2000) Circulation, 101, pp. 2510-2517; \n\nDurrington, P.N., Mackness, B., Mackness, M.I., Paraoxonase and atherosclerosis (2001) Arterioscler. Thromb Vasc Biol, 21, pp. 473-480; \n\nBrophy, V.H., Jampsa, R.L., Clendenning, J.B., Effects of 5' regulatory-region polymorphisms on paraoxonase-gene (PON1) expression (2001) Am J Hum Genet, 68, pp. 1428-1436; \n\nFortunato, G., Rubba, P., Panico, S., A paraoxonase gene polymorphism, PON 1 (55), as an independent risk factor for increased carotid intima-media thickness in middle-aged women (2003) Atherosclerosis, 167, pp. 141-148; \n\nWatzinger, N., Schmidt, H., Schumacher, M., Human paraoxonase 1 gene polymorphisms and the risk of coronary heart disease: A community-based study (2002) Cardiology, 98, pp. 116-122; \n\nMartinelli, N., Girelli, D., Olivieri, O., Interaction between smoking and PON2 Ser311Cys polymorphism as a determinant of the risk of myocardial infarction (2004) Eur J Clin Invest, 34, pp. 14-20; \n\nAviram, M., Billecke, S., Sorenson, R., Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: Selective action of human paraoxonase allozymes Q and R (1998) Arterioscler Thromb Vasc Biol, 18, pp. 1617-1624; \n\nDeakin, S.P., James, R.W., Genetic and environmental factors modulating serum concentrations and activities of the antioxidant enzyme paraoxonase-1 (2004) Clin Sci, 107, pp. 435-447; \n\nPuhl, H., Waeg, G., Esterbauer, H., Methods to determine oxidation of low-density lipoproteins (1994) Methods Enzymol, 233, pp. 425-441; \n\nWatson, A.D., Berliner, J.A., Hama, S.Y., Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein (1995) J Clin Invest, 96, pp. 2882-2891; \n\nAviram, M., Rosenblat, M., Bisgaier, C.L., Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase (1998) J Clin Invest, 101, pp. 1581-1590; \n\nvan Himbergen, T.M., van Tits, L.J., Hectors, M.P., Paraoxonase-1 and linoleic acid oxidation in familial hypercholesterolemia (2005) Biochem Biophys Res Commun, 333, pp. 787-793; \n\nRosenblat, M., Gaidukov, L., Khersonsky, O., The catalytic histidine dyad of high density lipoprotein-associated serum paraoxonase-1(PON1) is essential for PON1-mediated inhibition of low density lipoprotein oxidation and stimulation of macrophage cholesterol efflux (2006) J Biol Chem, 281, pp. 7657-7665; \n\nRoest, M., van Himbergen, T.M., Barendrecht, A.B., Genetic and environmental determinants of the PON-1 phenotype (2007) Eur J Clin Invest, 37, pp. 187-196; \n\nMiller, G.J., Miller, N.E., Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease (1975) Lancet, 1, pp. 16-19; \n\nBrites, F., Zago, V., Verona, J., HDL capacity to inhibit LDL oxidation in well-trained triathletes (2006) Life Sci, 78, pp. 3074-3081; \n\nShih, D.M., Gu, L., Hama, S., Genetic-dietary regulation of serum paraoxonase expression and its role in atherogenesis in a mouse model (1996) J Clin Invest, 97, pp. 1630-1639; \n\nTward, A., Xia, Y.R., Wang, X.P., Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice (2002) Circulation, 106, pp. 484-490; \n\nMackness, B., Davies, G.K., Turkie, W., Paraoxonase status in coronary heart disease: Are activity and concentration more important than genotype (2001) Arterioscler Thromb Vasc Biol, 21, pp. 1451-1457; \n\nSarkar, P.D., Shivaprakash, T.M., Madhusudhan, B., Association between paraoxonase activity and lipid levels in patients with premature coronary artery disease (2006) Clin Chim Acta, 373, pp. 77-81; \n\nRahmani, M., Raiszadeh, F., Allahverdian, S., Coronary artery disease is associated with the ratio of apolipoprotein A-1/B and serum concentration of apolipoprotein B, but not with paraoxonase enzyme activity in Iranian subjects (2002) Atherosclerosis, 162, pp. 381-389; \n\nMackness, B., Durrington, P., McElduff, P., Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study (2003) Circulation, 107, pp. 2775-2779; \n\nBhattacharyya, T., Nicholls, S.J., Topol, E.J., Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk (2008) JAMA, 299, pp. 1265-1276; \n\nRozenberg, O., Shih, D.M., Aviram, M., Human serum paraoxonase 1 decreases macrophage cholesterol biosynthesis: Possible role for its phospholipase-A2-like activity and lysophosphatidylcholine formation (2003) Arterioscler Thromb Vasc Biol, 23, pp. 461-467; \n\nSenti, M., Tomás, M., Fitó, M., Antioxidant paraoxonase 1 activity in the metabolic syndrome (2003) J Clin Endocrinol Metab, 88, pp. 5422-5426; \n\nNavab, M., Hama-Levy, S., van Lenten, B.J., Mildly oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio (1997) J Clin Invest, 99, pp. 2005-2019; \n\nOtocka-Kmiecik, A., Orłowska-Majdak, M., The role of genetic (PON1 polymorphism) and environmental factors, especially physical activity, in antioxidant function of paraoxonase (2009) Postepy Hig Med Dosw (Online), 63, pp. 668-677; \n\nCole, T.B., Jampsa, R.L., Walter, B.J., Expression of human paraoxonase (PON1) during development (2003) Pharmacogenetics, 13, pp. 357-364; \n\nSenti, M., Tomás, M., Vila, J., Relationship of age-related myocardial infarction risk and Gln/Arg 192 variants of the human paraoxonase1 gene: The REGICOR study (2001) Atherosclerosis, 156, pp. 443-449; \n\nGoldhammer, E., Ben-Sira, D., Zaid, G., Paraoxonase activity following exercise-based cardiac rehabilitation program (2007) J Cardiopulm Rehabil Prev, 27, pp. 151-154; \n\nAviram, M., Rosenblat, M., Billecke, S., Human serum paraoxonase (PON1) is inactivated by oxidised low density lipoprotein and preserved by antioxidants (1999) Free Radic Biol Med, 26, pp. 892-904; \n\nJaouad, L., Milochevitch, C., Khalil, A., PON1 paraoxonase activity is reduced during HDL oxidation and is an indicator of HDL antioxidant capacity (2003) Free Radic Res, 37, pp. 77-83; \n\nAviram, M., Dornfeld, L., Rosenblat, M., Pomegranate juice consumption reduces oxidative stress, atherogenic modification of LDL, and platelet aggregation: Studies in humans and in atherosclerotic apolipoprotein E-deficient mice (2000) Am J Clin Nutr, 71, pp. 1062-1076; \n\nFuhrman, B., Aviram, M., Preservation of paraoxonase activity by wine flavonoids: Possible role in protection of LDL from lipid peroxidation (2002) Ann NY Acad Sci, 957, pp. 321-324; \n\nHayek, T., Fuhrman, B., Vaya, J., Reduced progression of atherosclerosis in apolipoprotein E-deficient mice following consumption of red wine, or its polyphenols quercetin or catechin, is associated with reduced susceptibility of LDL to oxidation and aggregation (1997) Arterioscler Thromb Vasc Biol, 17, pp. 2744-2752; \n\nNguyen, S.D., Sok, D.E., Beneficial effect of oleolylated lipids on paraoxonase 1: Protection against oxidative inactivation and stabilization (2003) Biochem J, 375, pp. 275-285; \n\nKudchodkar, B.J., Lacko, A.G., Dory, L., Dietary fat modulates serum paraoxonase 1 activity in rats (2000) J Nutr, 130, pp. 2427-2433; \n\nBeer, S., Moren, X., Ruiz, J., Postprandial modulation of serum paraoxonase activity and concentration in diabetic and non-diabetic subjects (2006) Nutr Metab Cardiovasc Dis, 16, pp. 457-465; \n\nSorenson, R.C., Bisgaier, C.L., Aviram, M., Human serum Paraoxonase/Arylesterase's retained hydrophobic N-terminal leader sequence associates with HDLs by binding phospholipids: Apolipoprotein A-I stabilizes activity (1999) Arterioscler Thromb Vasc Biol, 19, pp. 2214-2225; \n\nRao, M.N., Marmillot, P., Gong, M., Light, but not heavy alcohol drinking stimulates paraoxonase by upregulating liver mRNA in rats and humans (2003) Metabolism, 52, pp. 1287-1294; \n\nHarats, D., Ben-Naim, M., Dabach, Y., Cigarette smoking renders LDL susceptible to peroxidative modification and enhanced metabolism by macrophages (1989) Atherosclerosis, 79, pp. 245-252; \n\nJames, R.W., Leviev, I., Righetti, A., Smoking is associated with reduced serum paraoxonase activity and concentration in patients with coronary artery disease (2000) Circulation, 101, pp. 2252-2257; \n\nAbbott, C.A., Mackness, M.I., Kumar, S., Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins (1995) Arterioscler Thromb Vasc Biol, 15, pp. 1812-1818; \n\nGrundy, S.M., Vega, G.L., Fibric acids: Effects on lipids and lipoprotein metabolism (1987) Am J Med, 83, pp. 9-20; \n\nShepherd, J., Cobbe, S.M., Ford, I., Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group (1995) N Engl J Med, 333, pp. 1301-1307; \n\nBellosta, S., Via, D., Canavesi, M., HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages (1998) Arterioscler Thromb Vasc Biol, 18, pp. 1671-1678; \n\nTakemoto, M., Liao, J.K., Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (2001) Arterioscler Thromb Vasc Biol, 21, pp. 1712-1719; \n\nNegre-Aminou, P., van Vliet, A.K., van Erck, M., Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors; comparison with other human cell types (1997) Biochim Biophys Acta, 1345, pp. 259-268; \n\nSzczeklik, A., Undas, A., Musial, J., Antithrombotic actions of statins (2001) Med Sci Monit, 7, pp. 1381-1385; \n\nDobrucki, L.W., Kalinowski, L., Dobrucki, I.T., Statin-stimulated nitric oxide release from endothelium (2001) Med Sci Monit, 7, pp. 622-627; \n\nMaron, D.J., Fazio, S., Linton, M.F., Current perspectives on statins (2000) Circulation, 101, pp. 207-213; \n\nNarita, Y., Kitazoe, Y., Kurihara, Y., Increase or decrease of HDL-cholesterol concentrations during pravastatin treatment depending on the pretreatment HDL cholesterol levels (1997) Eur J Clin Pharmacol, 52, pp. 461-463; \n\nStein, E.A., Lane, M., Laskarzewski, P., Comparison of statins in hypertriglyceridemia (1998) Am J Cardiol, 81, pp. 66-69; \n\nHoogerbrugge, N., Jansen, H., Atorvastatin increases low-density lipoprotein size and enhances high-density lipoprotein cholesterol concentration in male, but not in female patients with familial hypercholesterolemia (1999) Atherosclerosis, 146, pp. 167-174; \n\nCrouse III, J.R., Frohlich, J., Ose, L., Effects of high doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I (1999) Am J Cardiol, 83, pp. 1476-1477; \n\nWierzbicki, A.S., Lumb, P.J., Chik, G., Comparison of therapy with simvastatin 80 mg and atorvastatin 80 mg in patients with familial hypercholesterolaemia (1999) Int J Clin Pract, 53, pp. 609-611; \n\nRonald, S., Keany, J.F., Role of oxidative modification in atherosclerosis (2004) Physiol Res, 84, pp. 1381-1478; \n\nHarangi, M., Seres, I., Varga, Z., Atorvastatin effect on high-density lipoprotein-associated paraoxonase activity and oxidative DNA damage (2004) Eur J Clin Pharmacol, 60, pp. 685-691; \n\nKassai, A., Illyés, L., Mirdamadi, H.Z., The effect of atorvastatin therapy on lecithin: Cholesterol acyltransferase, cholesteryl ester transfer protein and the antioxidant paraoxonase (2007) Clin Biochem, 40, pp. 1-5; \n\nTomas, M., Senti, M., Garcia-Faria, F., Effect of simvastatin therapy on paraoxonase activity and related lipoproteins in familial hypercholesterolemic patients (2000) Arterioscler Thromb Vasc Biol, 20, pp. 2113-2119; \n\nDeakin, S., Leviev, I., Guernier, S., Simvastatin modulates expression of the PON1 gene and increases serum paraoxonase: A role for sterol regulatory element-binding protein-2 (2003) Arterioscler Thromb Vasc Biol, 23, pp. 2083-2089; \n\nFuhrman, B., Koren, L., Volkova, N., Atorvastatin therapy in hypercholesterolemic patients suppresses cellular uptake of oxidized-LDL by differentiating monocytes (2002) Atherosclerosis, 164, pp. 179-185; \n\nTsimihodimos, V., Karabina, S.A., Tambaki, A.P., Atorvastatin preferentially reduces LDL-associated platelet-activating factor acetylhydrolase activity in dyslipidemias of type IIA and type IIB (2002) Arterioscler Thromb Vasc Biol, 22, pp. 306-311; \n\nScharnagl, H., Schinker, R., Gierens, H., Effect of atorvastatin, simvastatin and lovastatin on the metabolism of cholesterol and triacylglycerides in HepG2 cells (2001) Biochem Pharmacol, 62, pp. 1545-1555; \n\nGouedard, C., Koum-Besson, N., Barouki, R., Opposite regulation of the human paraoxonase-1 gene PON-1 by fenofibrate and statins (2003) Mol Pharmacol, 63, pp. 945-956; \n\nBeltowski, J., Wojcicka, G., Mydlarczyk, M., Cerivastatin modulates plasma paraoxonase/arylesterase activity and oxidant-antioxidant balance in the rat (2002) Pol J Pharmacol, 54, pp. 143-150; \n\nBeltowski, J., Wojcicka, G., Jamroz, A., Differential effect of 3-hydroxy-3-methylglutarylcoenzyme A reductase inhibitors on plasma paraoxonase 1 activity in the rat (2002) Pol J Pharmacol, 54, pp. 661-671; \n\nGuichard, J.P., Prades Sauron, R.L., A comparison of the bioavailability of standard or micronized formulations of fenofibrate (1993) Curr Ther Res, 610, p. 54. , (una sola página); \n\nDurrington, P.N., Mackness, M.I., Bhatnagar, D., Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia (1998) Atherosclerosis, 138, pp. 217-225; \n\nTsimihodimos, V., Kakafika, A., Tambaki, A.P., Fenofibrate induces HDL-associated PAF-AH but attenuates enzyme activity associated with apoBcontaining lipoproteins (2003) J Lipid Res, 44, pp. 927-934; \n\nYesilbursa, D., Serdar, A., Saltan, Y., The effect of fenofibrate on serum paraoxonase activity and inflammatory markers in patients with combined hyperlipidemia (2005) Kardiol Pol, 62, pp. 526-530; \n\nTuray, J., Grnaková, V., Valka, J., Changes in paraoxonase and apolipoprotein A-I, B, C-III and E in subjects with combined familial hyperlipoproteinaemia treated with ciprofibrate (2000) Drug Exp Clin Res, 26, pp. 83-88; \n\nParagh, G., Balogh, Z., Seres, I., Effect of gemfibrozil on HDL-associated serum paraoxonase activity and lipoprotein profile in patients with hyperlipidaemia (2000) Clin Drug Invest, 19, pp. 277-282; \n\nBalogh, Z., Seres, I., Harangi, M., Kovacs, Gemfibrozil increases paraoxonase activity in type 2 diabetic patients: A new hypothesis of the beneficial action of fibrates? (2001) Diabetes Metab, 27, pp. 604-610; \n\nParagh, G., Seres, I., Harangi, M., Ciprofibrate increases paraoxonase activity in patients with metabolic syndrome (2006) Br J Clin Pharmacol, 61 (6), pp. 694-701; \n\nSchierf, G., Shwat, M., Feuerborn, E., Biliary and plasma lipids and lipid-lowering chemotherapy. Studies with clofibrate, fenofibrate and etofibrate in healthy volunteers (1980) Atherosclerosis, 36, pp. 323-329; \n\nParagh, G., Seres, I., Harangi, M., The effect of micronised fenofibrate on paraoxonase activity in patients with coronary heart disease (2003) Diabetes Metab, 29, pp. 613-618; \n\nPhuntuwate, W., Suthisisang, C., Koanantakul, B., Effect of fenofibrate therapy on paraoxonase1 status in patients with low HDL-C levels (2008) Atherosclerosis, 196, pp. 122-128; \n\nStaels, B., Dallongeville, J., Auwerx, J., Mechanism of action of fibrates on lipid and lipoprotein metabolism (1998) Circulation, 98, pp. 2088-2093; \n\nBełtowski, J., Wójcicka, G., Mydlarczyk, M., The effect of peroxisome proliferator-activated receptors a (PPARa) agonist, fenofibrate, on lipid peroxidation, total antioxidant capacity, and plasma paraoxonase 1 (PON 1) activity (2002) J Physiol Pharmacol, 53, pp. 463-475; \n\nAckerman, Z., Oron-Herman, M., Rosenthal, T., Effects of amlodipine, captopril, and bezafibrate on oxidative milieu in rats with fatty liver (2008) Dig Dis Sci, 53, pp. 777-784; \n\nEdgar, A.D., Tomkiewicz, C., Costet, P., Fenofibrate modifies transaminase gene expression via a peroxisome proliferator activated receptor alpha-dependent pathway (1998) Toxicol Lett, 98, pp. 13-23; \n\nVu-Dac, N., Chopin-Delannoy, S., Gervois, P., The nuclear receptors peroxisome proliferators activated receptor and Rev-erb mediate the species-specific regulation of apolipo protein A-I expression by fibrates (1998) J Biol Chem, 273, pp. 25713-25720; \n\nIşgör, M.M., Beydemir, S., Some cardiovascular therapeutics inhibit paraoxonase 1 (PON1) from human serum (2010) Eur J Pharmacol, 645, pp. 135-142; \n\nEkinci, D., Beydemir, S., Evaluation of the impacts of antibiotic drugs on PON 1; a major bioscavenger against cardiovascular diseases (2009) Eur J Pharmacol, 617, pp. 84-89; \n\nKiranoglu, S., Sinan, S., Gencer, N., In vivo effects of oral contraceptives on paraoxonase, catalase and carbonic anhydrase enzyme activities on mouse (2007) Biol Pharm Bull, 30, pp. 1048-1051", "hasCitationDuplums" : false, "userChangeableUntil" : "2016-02-21T15:57:34.000+0000", "publishDate" : "2015-11-23T15:57:34.000+0000", "directInstitutesForSort" : "", "ownerAuthorCount" : 11, "ownerInstituteCount" : 28, "directInstituteCount" : 0, "authorCount" : 5, "contributorCount" : 0, "hasQualityFactor" : false, "link" : "/api/publication/25176436", "label" : "Fridman O et al. Paraoxonase: Its multiple functions and pharmacological regulation. (2011) ARCHIVOS DE CARDIOLOGIA DE MEXICO 1405-9940 1665-1731 81 3 251-260", "template" : "